Skip to main content
Clinical Trials/IRCT20111107008022N13
IRCT20111107008022N13
Not yet recruiting
未知

Comparative bioequivalence study of two different Ciprofloxacin 500 mg formulations (Zagros Darou Pharmaceutical Company & reference) in 24 Iranian volunteers

Zagrous Darou Pharmaceutical Company0 sites24 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Zagrous Darou Pharmaceutical Company
Enrollment
24
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Zagrous Darou Pharmaceutical Company

Eligibility Criteria

Inclusion Criteria

  • Healthy male and female volunteers
  • Aged 18 to 45 years
  • Based on laboratory safety tests
  • No history of diseases affecting drug pharmacokinetic processes
  • Lack of any chronic or acute medication at least 1 week before the start of the study
  • Actual weight (TBW) in the range of 20% IBW

Exclusion Criteria

  • Subject showed clinically relevant deviations from normal in physical examination
  • Subject had undergone surgery of the gastrointestinal tract
  • Subject had donated a unit of blood or participated in another clinical trial, within the last three months before the first treatment
  • Subject had a history of alcohol abuse or smokes more than 10 cigarettes per day
  • Use any medication within 14 days before the first treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials